nach oben

CardioVascular and Interventional Radiology

Erschienen in:

01.12.2013 | Clinical Investigation

Clopidogrel Responsiveness in Patients Undergoing Peripheral Angioplasty

verfasst von: Georgios Pastromas, Stavros Spiliopoulos, Konstantinos Katsanos, Athanasios Diamantopoulos, Panagiotis Kitrou, Dimitrios Karnabatidis, Dimitrios Siablis

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To investigate the incidence and clinical significance of platelet responsiveness in patients receiving clopidogrel after peripheral angioplasty procedures.

Materials and Methods

This prospective study included patients receiving antiplatelet therapy with clopidogrel 75 mg after infrainguinal angioplasty or stenting and who presented to our department during routine follow-up. Clopidogrel responsiveness was tested using the VerifyNow P2Y12 Assay. Patients with residual platelet reactivity units (PRU) ≥ 235 were considered as nonresponders (NR group NR), whereas patients with PRU < 235 were considered as normal (responders [group R]). Primary end points were incidence of resistance to clopidogrel and target limb reintervention (TLR)-free survival, whereas secondary end points included limb salvage rates and the identification of any independent predictors influencing clinical outcomes.

Results

In total, 113 consecutive patients (mean age 69 ± 8 years) with 139 limbs were enrolled. After clopidogrel responsiveness analysis, 61 patients (53.9 %) with 73 limbs (52.5 %) were assigned to group R and 52 patients (46.1 %) with 66 limbs (47.5 %) to group NR. Mean follow-up interval was 27.7 ± 22.9 months (range 3–95). Diabetes mellitus, critical limb ischemia, and renal disease were associated with clopidogrel resistance (Fisher’s exact test; p < 0.05). According to Kaplan–Meier analysis, TLR-free survival was significantly superior in group R compared with group NR (20.7 vs. 1.9 %, respectively, at 7-year follow-up; p = 0.001), whereas resistance to clopidogrel was identified as the only independent predictor of decreased TLR-free survival (hazard rate 0.536, 95 % confidence interval 0.31–0.90; p = 0.01). Cumulative TLR rate was significantly increased in group NR compared with group R (71.2 % [52 of 73] vs. 31.8 % [21 of 66], respectively; p < 0.001). Limb salvage was similar in both groups.

Conclusion

Clopidogrel resistance was related with significantly more repeat interventions after peripheral angioplasty procedures.

Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, for the TASC II Working Group (2007) Inter-society consensus for the management of peripheral arterial disease (TASCII). J Vasc Surg 45:5–67CrossRef

The clopidogrel in unstable angina to prevent recurrent events trial investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494–502CrossRef

Mehta SR, Yusuf S, Peters RJ et al (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358:527–533PubMedCrossRef

Gurbel PA et al (2005) Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE post-stenting study. J Am Coll Cardiol 46:1820–1826PubMedCrossRef

Singh M et al (2006) Geographical differences in the rates of angiographic restenosis and ischemia- driven target vessel revascularization after percutaneous coronary interventions: results from the prevention of restenosis with tranilast and its outcomes (PRESTO) trial. J Am Coll Cardiol 47:34–39PubMedCrossRef

Serebruany VL, Steinhubl SR, Berger PB et al (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45:246–251PubMedCrossRef

Geisler T, Langer H, Wydymus M et al (2006) Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 27:2420–2425PubMedCrossRef

von Beckerath N, Pogatsa-Murray G, Wieczorek A et al (2006) Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost 95:910–911

Malinin A, Pokov A, Spergling M et al (2007) Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 119:277–284PubMedCrossRef

10.

Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354–362PubMedCrossRef

11.

Simon T, Verstuyft C, Mary-Krause M et al (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363–375PubMedCrossRef

12.

Gorchakova O, von Beckerath N, Gawaz M et al (2004) Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 25:1898–1902PubMedCrossRef

13.

Gilard M, Arnaud B, Cornily JC et al (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind omeprazole clopidogrel aspirin (OCLA) study. J Am Coll Cardiol 51:256–260PubMedCrossRef

14.

Tepe G, Bantleon R, Brechtel K, Schmehl J, Zeller T, Claussen CD et al (2012) Management of peripheral arterial interventions with mono or dual antiplatelet therapy-the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol 22(9):1998–2006PubMedCrossRef

15.

Jang J, Lim J, Chang K et al (2012) A Comparison of INNOVANCE^® PFA P2Y and VerifyNow P2Y12 assay for the assessment of clopidogrel resistance in patients undergoing percutaneous coronary intervention. J Clin Lab Anal 26(4):262–266PubMedCrossRef

16.

Price MJ, Endemann S, Gollapudi RR et al (2008) Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29(8):992–1000PubMedCrossRef

17.

Bonello L, Tantry US, Marcucci R et al (2010) Working group on high on-treatment platelet reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56(12):919–933PubMedCrossRef

18.

Karnabatidis D, Spiliopoulos S, Diamantopoulos A, Katsanos K, Kagadis GC, Kakkos S et al (2011) Primary everolimus-eluting stenting versus balloon angioplasty with bailout bare metal stenting of long infrapopliteal lesions for treatment of critical limb ischemia. J Endovasc Ther 18(1):1–12PubMedCrossRef

19.

Spiliopoulos S, Katsanos K, Karnabatidis D, Diamantopoulos A, Kagadis GC, Christeas N et al (2010) Cryoplasty versus conventional balloon angioplasty of the femoropopliteal artery in diabetic patients: long-term results from a prospective randomized single-center controlled trial. Cardiovasc Interv Radiol 33(5):929–938CrossRef

20.

Siablis D, Karnabatidis D, Katsanos K, Diamantopoulos A, Spiliopoulos S, Kagadis GC et al (2009) Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J Vasc Interv Radiol 20(9):1141–1150PubMedCrossRef

21.

Altenburg A, Haage P (2012) Antiplatelet and anticoagulant drugs in interventional radiology. Cardiovasc Interv Radiol 35:30–42CrossRef

22.

Nguyen TA, Diodati JG, Phar C (2005) Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45(8):1157–1164PubMedCrossRef

23.

El Ghannudi S, Ohlmann P, Jesel L et al (2011) Impaired inhibition of P2Y (12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention. Atherosclerosis 217(2):465–472PubMedCrossRef

24.

Rho GJ, Shin WR, Kong TS, Kim MS, Lee CJ, Lee BH (2011) Significance of clopidogrel resistance related to the stent-assisted angioplasty in patients with atherosclerotic cerebrovascular disease. J Korean Neurosurg Soc 50(1):40–44PubMedCrossRef

25.

Prabhakaran S, Wells KR, Lee VH, Flaherty CA, Lopes DK (2008) Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. AJNR Am J Neuroradiol 29(2):281–285PubMedCrossRef

26.

Muller C, Caillard S, Jesel L et al (2012) Association of estimated GFR with platelet inhibition in patients treated with clopidogrel. Am J Kidney Dis 59(6):777–785PubMedCrossRef

27.

Hall HM, Banerjee S, McGuire DK (2011) Variability of clopidogrel response in patients with type 2 diabetes mellitus. Diabetes Vasc Dis Res 8(4):245–253CrossRef

28.

Hamm CW, Bassand JP, Agewall S et al (2011) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. The task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 32:2999–3054PubMedCrossRef

29.

Alexopoulos D, Dimitropoulos G, Davlouros P et al (2011) Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. JACC Cardiovasc Interv 4(4):403–410PubMedCrossRef

30.

Alexopoulos D, Galati A, Xanthopoulou I et al (2012) Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol 60(3):193–199PubMedCrossRef

31.

Abergel E, Nikolsky E (2010) Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome. Vasc Health Risk Manag 6:963–977PubMed

32.

Trenk D, Stone GW, Gawaz M et al (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol 59(24):2159–2164PubMedCrossRef

Titel: Clopidogrel Responsiveness in Patients Undergoing Peripheral Angioplasty
verfasst von: Georgios Pastromas
Stavros Spiliopoulos
Konstantinos Katsanos
Athanasios Diamantopoulos
Panagiotis Kitrou
Dimitrios Karnabatidis
Dimitrios Siablis
Publikationsdatum: 01.12.2013
Verlag: Springer US
Erschienen in: CardioVascular and Interventional Radiology / Ausgabe 6/2013
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-013-0577-3

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Clopidogrel Responsiveness in Patients Undergoing Peripheral Angioplasty